News | April 07, 2008

MEDRAD, Battelle Win Award for Contrast Media Injection Device

April 8, 2008 - Battelle, a nonprofit independent research and development organization, and MEDRAD Inc. won a Medical Design Excellence Award (MDEA) for the MEDRAD XDS Extravasation Detector, a device for the enhancement of the safety of contrast media injection through early detection of extravasations.

Battelle worked closely with MEDRAD to develop the technology from exploration through product development. MEDRAD and Battelle jointly invented the electrical permittivity technology that enables XDS and developed the commercial product.

XDS continuously monitors the tissue immediately surrounding and directly beneath the injection site for changes in relative permittivity signaling fluid accumulation.

The MDEA competition is a prestigious program recognizing medical product excellence and the achievements of medical product manufacturers. An impartial, multidisciplinary panel of jurors with expertise in biomedical engineering, human factors, industrial design, medicine and diagnostics reviewed the entries and selected the winners.

MEDRAD and Battelle will accept the award at a ceremony on June 4, 2008 at the Medical Design & Manufacturing (MD&M) East 2008 Conference and Exposition in New York City. Additionally, the MEDRAD XDS Extravasation Detector will appear with the other MDEA winners in the April 7 issue of Medical Device & Diagnostic Industry (MD&DI).

For more information: www.medrad.com and www.battelle.org

Related Content

Iodine-based CT contrast with ready for scanning with a Canon Aquilion One 320-slice CT system at Northwestern Medicine Central DuPage Hospital in the Chicago suburbs. It is not clear that contrast caused contract induced nephrapathy (CIN), also referred to as acute kidney injury (AKI) or contrast-associated acute kidney injury (CAAKI),

Iodine-based CT contrast ready for scanning with a Canon Aquilion One 320-slice CT system at Northwestern Medicine Central DuPage Hospital in the Chicago suburbs.

Feature | Contrast Media | May 31, 2019 | Dave Fornell, Editor
Iodine-based contrast agents used in c
DyeMINISH Multi-center Global Patient Registry Launched
News | Contrast Media | May 09, 2019
Osprey Medical announced the launch of DyeMINISH, a global patient registry to evaluate the ongoing safety and...
VigiLanz and Cincinnati Children's Commercialize Real-Time Acute Kidney Injury Tracking
News | Contrast Media | November 30, 2018
VigiLanz and Cincinnati Children’s Hospital Medical Center recently announced a collaboration that leverages Cincinnati...
Gadolinium contrast agents (GBCAs) are partly retained in the brain, raising safety concerns, as seen in this MRI.

Gadolinium contrast agents (GBCAs) are partly retained in the brain, raising safety concerns, as seen in this MRI.

News | Contrast Media | September 12, 2018
In February 2018, a workshop was held at the National Institutes of Health (NIH) in Bethesda, Maryland, to explore co
Ligand Establishes Program to Develop Captisol-Enabled, Next-Generation Diagnostic Imaging Contrast Agents
News | Contrast Media | January 19, 2018
Ligand Pharmaceuticals Inc. announced initiation of a program to develop contrast agents with reduced renal toxicity....
FDA Holds MIDAC Meeting on Gadolinium-Based Contrast Agents. Image by Marilyn Fornell
News | Contrast Media | September 07, 2017
The U.S. Food and Drug Administration (FDA) announced it would hold a meeting of the Medical Imaging Drugs Advisory...
European Medicines Agency Issues Update on Gadolinium Contrast Agents
News | Contrast Media | August 29, 2017
August 29, 2017 — The European Medicines Agency (EMA) issued a final opinion that recommended restricting the use of
Guerbet Announces Plans to Streamline Contrast Media Portfolio, gadolinium MRI contrast
News | Contrast Media | July 18, 2017
Guerbet recently announced that it will phase out sales throughout the world of two products: Hexabrix (meglumine and...
Overlay Init